Zoetis (ZTS) Change in Accured Expenses (2014 - 2026)
Zoetis' (ZTS) quarterly Change in Accured Expenses came in at -$234.0 million in Q1 2026, down 13.59% year-on-year from -$270.8 million in Q1 2025, and down 365.91% on a QoQ basis from $88.0 million in Q4 2025.
Zoetis (ZTS) Change in Accured Expenses (2014 - 2026) Analysis & Trends
Zoetis (ZTS) has 13 years of Change in Accured Expenses data on file, last reported at -$234.0 million in Q1 2026.
- On a quarterly basis, Change in Accured Expenses fell 13.59% year-over-year to -$234.0 million in Q1 2026; TTM through Mar 2026 was $57.0 million, a 72.73% increase from a year earlier, with the FY2025 full-year figure at $85.0 million, down 25.44% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$234.0 million, down from $88.0 million in the prior quarter.
- Over the last five years, Change in Accured Expenses for ZTS reached as high as $124.0 million in Q3 2024 and fell as low as -$234.0 million in Q1 2026.
- Historically, Change in Accured Expenses has averaged -$8.7 million across 5 years, with a median of $32.0 million in 2023.
- Across the five-year window, Change in Accured Expenses sank 208.33% in 2022 and soared 825.0% in 2024, its largest moves.
- Year by year, Change in Accured Expenses stood at $47.0 million in 2022, then jumped by 100.0% to $94.0 million in 2023, then declined by 17.02% to $78.0 million in 2024, then grew by 12.82% to $88.0 million in 2025, then plunged by 365.91% to -$234.0 million in 2026.
- Per Business Quant data, the three most recent Change in Accured Expenses figures were -$234.0 million in Q1 2026, $88.0 million in Q4 2025, and $101.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | -12.70 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -234.00 Mn |
| Mar 31, 2026 | -234.00 Mn |
| Dec 31, 2025 | 88.00 Mn |
| Dec 31, 2025 | 88.00 Mn |
| Sep 30, 2025 | 101.00 Mn |
| Sep 30, 2025 | 101.00 Mn |
| Jun 30, 2025 | 102.00 Mn |
| Jun 30, 2025 | 102.00 Mn |
| Mar 31, 2025 | -206.00 Mn |
| Mar 31, 2025 | -206.00 Mn |
| Dec 31, 2024 | 78.00 Mn |
| Dec 31, 2024 | 78.00 Mn |
| Sep 30, 2024 | 124.00 Mn |
| Sep 30, 2024 | 124.00 Mn |
| Jun 30, 2024 | 37.00 Mn |
| Jun 30, 2024 | 37.00 Mn |
| Mar 31, 2024 | -125.00 Mn |
| Mar 31, 2024 | -125.00 Mn |
| Dec 31, 2023 | 94.00 Mn |
| Dec 31, 2023 | 94.00 Mn |